Lung Cancer Clinical Trials in Xi’an, Shanxi
12 recruitingXi’an, Shanxi, China
Showing 1–12 of 12 trials
Recruiting
Phase 3
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Small Cell Lung Cancer
Akeso560 enrolled53 locationsNCT07010263
Recruiting
Phase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-small Cell Lung Cancer (NSCLC)
Amgen750 enrolled379 locationsNCT05920356
Recruiting
Phase 3
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
Non-small Cell Lung Cancer
OncoC4, Inc.630 enrolled152 locationsNCT05671510
Recruiting
Phase 1
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
MelanomaNon-small Cell Lung CancerRenal Cell Carcinoma
Shanghai Henlius Biotech174 enrolled69 locationsNCT07160335
Recruiting
Phase 3
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
Non-small Cell Lung Cancer
Nuvation Bio Inc.138 enrolled29 locationsNCT06564324
Recruiting
Phase 2
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Non-small Cell Lung CancerNasopharyngeal Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.121 enrolled16 locationsNCT05956587
Recruiting
Phase 1Phase 2
A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
Non-small Cell Lung Cancer
Allist Pharmaceuticals, Inc.104 enrolled21 locationsNCT05276726
Recruiting
Phase 3
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
Advanced Non-squamous Non-small-cell Lung CancerMetastatic Non-Squamous Non-Small Cell Lung Cancer
Allist Pharmaceuticals, Inc.392 enrolled37 locationsNCT06416410
Recruiting
A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC
Non-small Cell Lung Cancer
Shanghai Chest Hospital305 enrolled11 locationsNCT06443684
Recruiting
A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China
Liver CancerPancreatic CancerGastric Cancer+8 more
Zhujiang Hospital12,000 enrolled50 locationsNCT05638269
Recruiting
Phase 3
D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
Non-small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.522 enrolled86 locationsNCT06300177
Recruiting
An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis
CNS MetastasesEGF-R Positive Non-Small Cell Lung Cancer
Tang-Du Hospital30 enrolled1 locationNCT06352502